세계의 인유두종바이러스(HPV) 거대세포바이러스(CMV) 치료제 시장 보고서(2025년)

Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Global Market Report 2025

US $ 4,490 ￦ 6,222,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 8,993,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,765,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

인유두종바이러스(HPV) 거대세포바이러스(CMV) 치료제 시장 규모는 향후 몇 년 동안 강력한 성장세를 보이며 2029년까지 8.7%의 연평균 복합 성장률(CAGR)로 68억 9,000만 달러에 이를 것으로 예측됩니다. 예측 기간 동안의 성장은 개발도상국의 의료 인프라 확대, 암 예방에 대한 정부의 이니셔티브, R&D 자금 증가, 면역 결핍 질환의 발병률 증가, 세계 의료비 증가 등의 요인에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 치료용 백신 개발의 진전, 새로운 항바이러스제 개발, 진단에 인공지능의 통합, 면역치료 접근법의 등장, CRISPR 및 유전자 편집 기술의 활용 등을 꼽을 수 있습니다.

자궁경부암의 유병률 증가는 인유두종바이러스(HPV) 및 거대세포바이러스(CMV) 치료제 시장의 성장을 가속할 것으로 예측됩니다. 자궁경부암은 자궁경부(자궁의 아래쪽에서 질로 이어지는 부분)에 발생하는 악성 종양으로, 주로 고위험군 HPV의 지속적인 감염으로 인해 증가하고 있습니다. HPV 및 CMV 치료제는 자궁경부 세포에 비정상적인 변화를 일으켜 조기에 발견하고 치료하지 않으면 암으로 발전할 수 있으며, HPV 및 CMV 치료제는 자궁경부암 관리에 있어 바이러스에 의한 질환의 진행을 표적으로 하여 환자의 예후를 개선함으로써 중요한 역할을 하고 있습니다. 중요한 역할을 하고 있습니다. 장기적인 건강과 삶의 질을 향상시키는 항바이러스 치료와 면역요법을 제공함으로써 암의 위험을 줄이는 데 도움을 주고 있습니다. 예를 들어, 2024년 4월 미국암협회가 발표한 보고서에 따르면, 2022년 전 세계에서 새로 자궁경부암 진단을 받은 환자는 약 2,000만 명이며, 2050년에는 이 숫자가 3,500만 명으로 늘어날 것으로 예측했습니다. 이러한 자궁경부암 유병률 증가가 HPV 및 CMV 치료 시장의 성장을 가속하고 있습니다.

HPV 및 CMV 치료제 시장의 주요 기업들은 미충족 의료 수요를 충족하고, 치료 효과를 높이고, 기존 치료제에 대한 내성을 낮추며, 면역 결핍 환자의 결과를 개선하기 위해 이식 후 항 거대세포바이러스(CMV) 치료와 같은 혁신적 솔루션 개발에 주력하고 있습니다. 이식 후 항CMV 치료는 면역 억제에 따른 장기 이식 및 줄기세포 이식 환자의 CMV 감염을 예방하고 관리하는 것을 목적으로 합니다. 예를 들어, 일본 다케다제약은 2024년 6월 일본 후생노동성으로부터 리브텐시티(성분명: 마리바비르)를 기존 항CMV 약물에 내성을 보이는 이식 후 CMV 감염 또는 질환의 치료제로 승인받았습니다. 리브텐시티는 CMV에 특이적인 UL97 단백질 키나아제를 특이적으로 표적으로 억제하는 국내 유일의 치료제로, 기존 치료제와는 다른 새로운 작용기전을 가진 획기적인 항바이러스제입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나재난과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계 인유두종바이러스(HPV) 거대세포바이러스(CMV) 치료제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업 분석
• 세계의 인유두종바이러스(HPV) 거대세포바이러스(CMV) 치료제 시장 : 성장률 분석
• 세계의 인유두종바이러스(HPV) 거대세포바이러스(CMV) 치료제 시장 실적 : 규모와 성장, 2019-2024년
• 세계의 인유두종바이러스(HPV) 거대세포바이러스(CMV) 치료제 시장 예측 : 규모와 성장, 2024-2029년, 2034년
• 세계 인유두종바이러스(HPV) 거대세포바이러스(CMV) 치료제 전체 시장(TAM)

제6장 시장 세분화

• 세계의 인유두종바이러스(HPV) 거대세포바이러스(CMV) 치료제 시장 : 치료 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 백신
• 항바이러스제
• 면역치료
• 세계의 인유두종바이러스(HPV) 거대세포바이러스(CMV) 치료제 시장 : 투여 경로별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 근육내
• 경구
• 국소
• 세계의 인유두종바이러스(HPV) 거대세포바이러스(CMV) 치료제 시장 : 적응증별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 자궁경부암
• 생식기 사마귀
• 두경부암
• 항문암
• 세계의 인유두종바이러스(HPV) 거대세포바이러스(CMV) 치료제 시장 : 유통 채널별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 병원
• 소매 약국
• 온라인 약국
• 전문 클리닉
• 세계의 인유두종바이러스(HPV) 거대세포바이러스(CMV) 치료제 시장 : 백신 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 예방 백신
• 치료 백신
• 재조합 백신
• 생약독화 백신
• 바이러스 님 입자(VLP) 기반 백신
• 세계의 인유두종바이러스(HPV) 거대세포바이러스(CMV) 치료제 시장 : 항바이러스제 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 뉴클레오사이드 유사체
• 비뉴클레오사이드 역전사효소 억제제(NNRTI)
• 프로테아제 억제제
• 데옥시리보핵산 중합효소 억제제
• 헬리카제-프리마제 억제제
• 세계의 인유두종바이러스(HPV) 거대세포바이러스(CMV) 치료제 시장 : 면역치료 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 단일클론항체
• 면역관문억제제
• 치료용 사이토카인
• 양자 T세포 치료

제7장 지역별/국가별 분석

• 세계의 인유두종바이러스(HPV) 거대세포바이러스(CMV) 치료제 시장 : 지역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 세계의 인유두종바이러스(HPV) 거대세포바이러스(CMV) 치료제 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 인유두종바이러스(HPV) 거대세포바이러스(CMV) 치료제 시장 : 경쟁 구도
• 인유두종바이러스(HPV) 거대세포바이러스(CMV) 치료제 시장 : 기업 개요
  • Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
  • F. Hoffmann-La Roche AG : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
  • AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Bayer AG : 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Sanofi S.A.
• Bristol Myers Squibb Company
• Thermo Fisher Scientific Inc.
• AstraZeneca plc
• Novartis AG
• GlaxoSmithKline(GSK) plc
• Takeda Pharmaceutical Company Limited
• Gilead Sciences Inc.
• Amgen Inc.
• Moderna Inc.
• BioNTech SE
• Boehringer Ingelheim International GmbH
• Cepheid Inc.
• QIAGEN N.V.
• Vir Biotechnology Inc.

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

• 인유두종바이러스(HPV) 거대세포바이러스(CMV) 치료제 시장, 2029년 : 새로운 기회를 제공하는 국가
• 인유두종바이러스(HPV) 거대세포바이러스(CMV) 치료제 시장, 2029년 : 새로운 기회를 제공하는 부문
• 인유두종바이러스(HPV) 거대세포바이러스(CMV) 치료제 시장, 2029년 : 성장 전략
  • 시장 동향에 근거한 전략
  • 경쟁 전략

제36장 부록

LSH

영문 목차

영문목차

Human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics refer to medical treatments aimed at managing, reducing, or eliminating infections caused by HPV and CMV. These treatments focus on controlling viral replication, preventing disease progression, and alleviating symptoms associated with conditions such as cervical cancer (HPV) and congenital infections or complications in immunocompromised individuals (CMV).

The main therapeutic types in the HPV and CMV therapeutics market include vaccines, antiviral drugs, and immunotherapy. Vaccines are biological formulations designed to induce immunity against specific infectious diseases. These vaccines are administered through various routes, including intramuscular, oral, and topical. The primary indications for these treatments include cervical cancer, genital warts, head and neck cancer, and anal cancer. Distribution channels for these therapeutics include hospitals, retail pharmacies, online pharmacies, and specialty clinics.

The human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic market research report is one of a series of new reports from The Business Research Company that provides human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic market statistics, including human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic industry global market size, regional shares, competitors with an human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic market share, detailed human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic market segments, market trends and opportunities, and any further data you may need to thrive in the human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic industry. The human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic market size has grown strongly in recent years. It will grow from $4.55 billion in 2024 to $4.95 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth during the historic period can be attributed to factors such as the increasing prevalence of human papillomavirus (HPV) and cytomegalovirus (CMV) infections, growing awareness of sexually transmitted infections, the development of antiviral drugs and vaccines, the rising incidence of HPV-related cancers, and public health vaccination initiatives.

The human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic market size is expected to see strong growth in the next few years. It will grow to $6.89 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth during the forecast period can be attributed to factors such as the expansion of healthcare infrastructure in developing countries, government initiatives for cancer prevention, increased funding for research and development, the growing incidence of immunocompromised conditions, and rising healthcare expenditure worldwide. Key trends in the forecast period include advancements in therapeutic vaccine development, the creation of novel antiviral agents, the integration of artificial intelligence in diagnostics, the emergence of immunotherapy approaches, and the utilization of CRISPR and gene-editing technologies.

The increasing prevalence of cervical cancer is expected to drive the growth of the human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutic market. Cervical cancer, a malignant tumor that develops in the cervix, the lower part of the uterus that connects to the vagina, is primarily rising due to persistent infections with high-risk strains of HPV. These infections cause abnormal changes in cervical cells that can develop into cancer if not detected and treated early. HPV and CMV therapeutics play a vital role in managing cervical cancer by targeting the virus-driven disease progression and improving patient outcomes. They help reduce the risk of cancer by providing antiviral treatments and immunotherapies that enhance long-term health and quality of life. For example, a report by the American Cancer Society in April 2024 revealed that approximately 20 million new cervical cancer cases were diagnosed globally in 2022, with projections showing this number could rise to 35 million by 2050. This increasing prevalence of cervical cancer is propelling the growth of the HPV and CMV therapeutic market.

Leading companies in the HPV and CMV therapeutics market are focusing on the development of innovative solutions, such as post-transplant anti-cytomegalovirus (CMV) treatments, to address unmet medical needs, enhance treatment efficacy, reduce resistance to existing therapies, and improve outcomes for immunocompromised patients. Post-transplant anti-CMV treatments are designed to prevent or manage CMV infections in organ or stem cell transplant recipients who are at high risk due to immunosuppression. For instance, in June 2024, Takeda Pharmaceutical Company Limited, based in Japan, received approval from the Japanese Ministry of Health, Labour, and Welfare (MHLW) for LIVTENCITY (maribavir) to treat post-transplant CMV infections or diseases that are resistant to current anti-CMV medications. This innovative antiviral agent is the only treatment in Japan that specifically targets and inhibits the cytomegalovirus (CMV)-specific UL97 protein kinase, offering a new mechanism of action distinct from traditional therapies.

In May 2022, Cheplapharm Arzneimittel GmbH, a pharmaceutical company based in Germany, acquired the rights to Valcyte from F. Hoffmann-La Roche AG. With this acquisition, Cheplapharm aims to expand its antiviral portfolio by adding Valcyte, a drug primarily used to treat cytomegalovirus (CMV) infections in transplant patients. F. Hoffmann-La Roche AG, a healthcare and pharmaceutical company based in Switzerland, specializes in developing and marketing Valcyte for CMV infections.

Major players in the human papillomavirus (hpv) cytomegalovirus (cmv) therapeutic market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca plc, Novartis AG, GlaxoSmithKline (GSK) plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Boehringer Ingelheim International GmbH, Cepheid Inc., QIAGEN N.V., Vir Biotechnology Inc., Meridian Bioscience Inc.

North America was the largest region in the human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The human papillomavirus (HPV) cytomegalovirus (CMV) therapeutic market consists of revenues earned by entities providing specific services such as antiviral drug infusion and dispensing, therapeutic vaccine administration, genotypic resistance testing, viral load monitoring, patient counselling and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutic market also includes sales of antiviral medications, therapeutic vaccines targeting human papillomavirus strains, immunomodulators, monoclonal antibodies, and gene therapy-based treatments. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on human papillomavirus (hpv) cytomegalovirus (cmv) therapeutic market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for human papillomavirus (hpv) cytomegalovirus (cmv) therapeutic ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The human papillomavirus (hpv) cytomegalovirus (cmv) therapeutic market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapeutic Types: Vaccines; Antiviral Drugs; Immunotherapy
• 2) By Route of Administration: Intramuscular; Oral; Topical
• 3) By Indications: Cervical Cancer; Genital Warts; Head And Neck Cancer; Anal Cancer
• 4) By Distribution Channel: Hospitals; Retail Pharmacies; Online Pharmacies; Specialty Clinics
• Subsegments:
• 1) By Vaccines: Prophylactic Vaccines; Therapeutic Vaccines; Recombinant Vaccines; Live Attenuated Vaccines; Virus-Like Particle (VLP) Based Vaccines
• 2) By Antiviral Drugs: Nucleoside Analogues; Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs); Protease Inhibitors; Deoxyribonucleic Acid Polymerase Inhibitors; Helicase-Primase Inhibitors
• 3) By Immunotherapy: Monoclonal Antibodies; Immune Checkpoint Inhibitors; Therapeutic Cytokines; Adoptive T-cell Therapy
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Characteristics

3. Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Trends And Strategies

4. Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Growth Analysis And Strategic Analysis Framework

• 5.1. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Growth Rate Analysis
• 5.4. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Total Addressable Market (TAM)

6. Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Segmentation

• 6.1. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vaccines
• Antiviral Drugs
• Immunotherapy
• 6.2. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intramuscular
• Oral
• Topical
• 6.3. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cervical Cancer
• Genital Warts
• Head And Neck Cancer
• Anal Cancer
• 6.4. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Retail Pharmacies
• Online Pharmacies
• Specialty Clinics
• 6.5. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prophylactic Vaccines
• Therapeutic Vaccines
• Recombinant Vaccines
• Live Attenuated Vaccines
• Virus-Like Particle (VLP) Based Vaccines
• 6.6. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Sub-Segmentation Of Antiviral Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nucleoside Analogues
• Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
• Protease Inhibitors
• Deoxyribonucleic Acid Polymerase Inhibitors
• Helicase-Primase Inhibitors
• 6.7. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Immune Checkpoint Inhibitors
• Therapeutic Cytokines
• Adoptive T-cell Therapy

7. Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Regional And Country Analysis

• 7.1. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 8.1. Asia-Pacific Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 9.1. China Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Overview
• 9.2. China Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 10.1. India Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 11.1. Japan Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Overview
• 11.2. Japan Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 12.1. Australia Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 13.1. Indonesia Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 14.1. South Korea Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Overview
• 14.2. South Korea Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 15.1. Western Europe Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Overview
• 15.2. Western Europe Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 16.1. UK Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 17.1. Germany Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 18.1. France Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 19.1. Italy Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 20.1. Spain Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 21.1. Eastern Europe Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Overview
• 21.2. Eastern Europe Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 22.1. Russia Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 23.1. North America Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Overview
• 23.2. North America Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 24.1. USA Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Overview
• 24.2. USA Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 25.1. Canada Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Overview
• 25.2. Canada Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 26.1. South America Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Overview
• 26.2. South America Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 27.1. Brazil Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 28.1. Middle East Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Overview
• 28.2. Middle East Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

• 29.1. Africa Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Overview
• 29.2. Africa Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Therapeutic Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Competitive Landscape And Company Profiles

• 30.1. Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Competitive Landscape
• 30.2. Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. Bristol Myers Squibb Company
• 31.3. Thermo Fisher Scientific Inc.
• 31.4. AstraZeneca plc
• 31.5. Novartis AG
• 31.6. GlaxoSmithKline (GSK) plc
• 31.7. Takeda Pharmaceutical Company Limited
• 31.8. Gilead Sciences Inc.
• 31.9. Amgen Inc.
• 31.10. Moderna Inc.
• 31.11. BioNTech SE
• 31.12. Boehringer Ingelheim International GmbH
• 31.13. Cepheid Inc.
• 31.14. QIAGEN N.V.
• 31.15. Vir Biotechnology Inc.

32. Global Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

34. Recent Developments In The Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market

35. Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market High Potential Countries, Segments and Strategies

• 35.1 Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Human Papillomavirus (HPV) Cytomegalovirus (CMV) Therapeutic Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료